Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Opus Genetics › Adage Capital Management, L.P. cut its IRD stake below 5% (2.7%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 12, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000919574-26-007560
Data quality Verified: identifiers matched exactly
Around the same time Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
George Magrath (Chief Executive Officer) sold ~$110K of Opus Genetics
Automatic saleFiled 12d ago The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 6, 2026 Company filing · Form 8-K · Results Reported its results Sep 30, 2026 Insider Director sold ~$2.76M of IRD shares in the open market What came next Oct 19, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company’s Chief Scientific and Development Officer, effective as of October 19, 2026 (the “Separation Date”).” Oct 23, 2026 Insider · 4 people Insiders: 5 sales (~$218K) Oct 27, 2026 5% stake BlackRock, Inc. reported a passive stake (13G) of 6.1% Nov 3, 2026 Insider CEO sold ~$110K of IRD shares in the open market Nov 10, 2026 Company filing · Form 8-K · Results Reported its results Nov 12, 2026 5% stake Adage Capital Management, L.P. reported a passive stake (13G) of 2.7% Nov 16, 2026 5% stake Caligan Partners LP reported a passive stake (13G) of 6.2% Nov 16, 2026 5% stake Boxer Capital Management, LLC reported a passive stake (13G) of 5.4% Nov 16, 2026 5% stake Perceptive Advisors LLC reported a passive stake (13G) of 10.0% Nov 16, 2026 5% stake BALYASNY ASSET MANAGEMENT L.P. reported a passive stake (13G) of 7.4% Nov 16, 2026 5% stake Cormorant Asset Management, LP reported a passive stake (13G) of 6.6%